<DOC>
	<DOCNO>NCT00916045</DOCNO>
	<brief_summary>The purpose study determine safety feasibility unrelated double single cord blood transplantation patient haematological malignancy use reduced-intensity myeloablative conditioning regimen .</brief_summary>
	<brief_title>Pilot Study Unrelated Cord Blood Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE INCLUSION CRITERIA : In general encompasses haematological disorder volunteer unrelated donor transplant clinically indicate . 1 . Acute , chronic leukaemia myelodysplastic syndrome allogeneic transplantation consider best treatment option . 1 . Acute myeloid leukaemia ( AML ) first complete remission ( CR1 ) one follow characteristic : High risk cytogenetic molecular alteration ( e.g . ( 9 ; 22 ) , deletion 7/7q , monosomy 5 del ( 5q ) , 3q26 alteration , complex karyotype [ 3 anomaly ] , p53 alteration , 11q23 especially ( 6 ; 11 ) abnormality , FLT3 ITD ) Leukocytes diagnosis &gt; 50 x109/l ( except case good prognosis molecular rearrangement leukocytes &gt; 100 x 109/l ) 2 . Myelodysplastic syndrome International Prognosis Index ( IPSS ) 1 ( intermediate group 2 high risk ) IPSS 0 0.5 presence cytopenia require treatment . 3 . Therapy related AML MDS first CR 4 . AML MDS second ( CR2 ) subsequent CR 5 . Ph'positive chronic myeloid leukaemia . In first chronic phase refractory and/or intolerance tyrosine kinase inhibitor clearly demonstrate ii . In second chronic phase 2 . Acute lymphoblastic leukaemia ( ALL ) . In CR1 one follow characteristic : . Very high risk chromosome molecular alteration ( e.g . ( 9 ; 22 ) , ( 4 ; 11 ) , complex karyotype adult , bcr/abl rearrangement , MLL rearrangement ) ii . Slow response induction treatment define presence &gt; 10 % blast bone marrow day 14 induction treatment iii . Adults age &gt; 30 year iv . Adults B ALL cell line number leukocytes diagnosis &gt; 25 x 109/L T ALL cell line number leukocytes diagnosis &gt; 100X109/L b . In CR2 subsequent CR 3 . NonHodgkin 's lymphoma 1 . Follicular NHL : second subsequent complete partial remission 2 . Mantle cell NHL : second subsequent complete partial remission 3 . High grade NHL : second complete good partial remission 4 . Hodgkin 's disease a. second subsequent complete partial remission 5 . Chronic lymphocytic leukaemia . 1. second subsequent remission 2. adverse risk prognostic feature first remission 6 . Acquired bone marrow failure syndromes 7 . Other haematological malignancy UD bone marrow transplantation indicate PATIENT SELECTION Inclusion criterion : myeloablative condition regimen 1 . Aged 35 year great 18 year 2 . Absence HLA compatible relate donor . 3 . Need urgent transplantation absence HLAcompatible VUD search international registry . 4 . Patients HLAcompatible VUD whose donor consider transplantation centre unsuitable also eligible . 5 . Availability suitable UDUCB unit/s . 6 . Informed consent . Exclusion criterion : myeloablative condition regimen 1 . Patients available 56/6 HLAA , B , DRB1 match sibling donor 10/10 unrelated bone marrow donor 2 . ECOG performance status worse 2 3 . Cardiac insufficiency require treatment , symptomatic coronary artery disease LVEF le 40 % . 4 . Hepatic disease , total bilirubin 20umol/l AST &gt; 3 time upper limit normal . 5 . Severe hypoxaemia , pO2 &lt; 70 mm Hg , decrease DLCO &lt; 70 % predict ; mild hypoxemia , pO2 &lt; 80 mm Hg severely decrease DLCO &lt; 60 % predict . 6 . Impaired renal function ( creatinine &gt; 2 time upper limit normal creatinine clearance &lt; 50 % age , gender , weight ) . 7 . Patients receive previous treatment Thymoglobulin® 8 . HIV HTLV positive patient . 9 . Female patient pregnant breast feeding due risk foetus condition regimen potential risk nurse infant . 10 . Life expectancy severely limited disease disease indication transplant 11 . Serious concurrent untreated infection e.g . active tuberculosis , mycoses viral infection 12 . Serious psychiatric/ psychological disorder 13 . Absence /inability provide inform consent 14 . Serious disease prevent treatment chemotherapy 15 . Myelofibrosis Inclusion criterion : reducedintensity condition regimen ( For FluMel &amp; FluCyTBI regimens ) : 1 . Age 70 year old 18 year 2 . Absence HLA compatible relate donor . 3 . Need urgent transplantation absence HLAcompatible VUD search international registry . 4 . Patients HLAcompatible VUD whose donor consider transplantation centre unsuitable also eligible . 5 . Availability suitable UDUCB unit/s . 6 . Informed consent . reducedintensity condition regimen ( For FluMel &amp; FluCyTBI regimens ) : 1 . Patients available 56/6 HLAA , B , DRB1 match sibling donor 10/10 unrelated bone marrow donor 2 . ECOG performance status worse 2 3 . Cardiac insufficiency require treatment , symptomatic coronary artery disease LVEF le 35 % . 4 . Hepatic disease , total bilirubin great 2 time upper limit normal AST &gt; 5 time upper limit normal . 5 . Severe hypoxaemia , pO2 &lt; 70 mm Hg , decrease DLCO &lt; 50 % predict ; mild hypoxemia , pO2 &lt; 80 mm Hg severely decrease DLCO &lt; 50 % predict . 6 . Impaired renal function ( creatinine &gt; 2 time upper limit normal creatinine clearance &lt; 50 % age , gender , weight ) . 7 . Previous irradiation precludes safe administration additional dose 200 cGy total body irradiation ( TBI ) . 8 . Patients receive previous treatment Thymoglobulin® 9 . HIV HTLV positive patient . 10 . Female patient pregnant breast feeding due risk foetus condition regimen potential risk nurse infant . 11 . Life expectancy severely limited disease disease indication transplant 12 . Serious concurrent uncontrolled infection e.g . active tuberculosis , mycoses viral infection 13 . Serious psychiatric/ psychological disorder 14 . Absence /inability provide inform consent 15 . Within 6 month prior myeloablative transplant . 16 . Patients acute leukaemia morphological relapse/ persistent/ progressive disease 17 . Intermediate high grade NHL , mantle cell NHL Hodgkin 's disease refractory progressive salvage therapy . 18 . Myelofibrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>